Jeffrey S. Hackman - 19 May 2022 Form 3/A - Amendment Insider Report for Comera Life Sciences Holdings, Inc.

Role: Chairman, President and Chief Executive Officer., Director
Signature: /s/ Ryan M. Rourke Reed, Attorney-in-Fact
Issuer symbol: CMRA on OTC
Transactions as of: 19 May 2022
Net transactions value: $0
Form type: 3/A - Amendment
Filing time: 14 Feb 2023, 16:12:28 UTC
Date Of Original Report: 20 May 2022
Next filing: 11 Aug 2022
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	CMRA	Stock Option (Right to Buy)							19 May 2022	Common Stock	277,598	$0.5900	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This Form 3/A is being filed to correct information previously disclosed on the original Form 3 filed by the reporting person on May 20, 2022, including the Exercise Price, Expiration Date, Amount or Number of Shares and vesting schedule of the stock option grant.
F2	This option was issued pursuant to the terms of a business combination agreement involving the issuer and Comera Life Sciences, Inc. in exchange for a comparable option previously issued by such company on September 16, 2021. 25% of the option vests or vested on the one year anniversary of the grant date and in equal monthly installments thereafter for 36 months.

Remarks:

Chairman, President and Chief Executive Officer.